Welcome to our dedicated page for Kintara Therapeutics news (Ticker: KTRA), a resource for investors and traders seeking the latest updates and insights on Kintara Therapeutics stock.
Kintara Therapeutics Inc. (KTRA) news has centered on the issuer's biotechnology and immuno-oncology disclosure stream as recent records identify the company as TuHURA Biosciences, Inc. TuHURA is a Phase 3 immuno-oncology company developing therapeutics intended to overcome resistance to cancer immunotherapy.
Recurring developments include clinical-development leadership and strategy for the VISTA-inhibiting antibody TBS-2025 in blood-related cancers, innate immune agonist product candidates, Delta Opioid Receptor technology, antibody-drug conjugate work targeting Myeloid Derived Suppressor Cells, and updates on capital structure, material agreements, shareholder voting, governance, operating results, and risk factors.
Kintara Therapeutics (Nasdaq: KTRA) will have its CEO, Saiid Zarrabian, present at the LD Micro 500 virtual conference on September 3, 2020, at 4:00 PM ET. The presentation will be followed by a live Q&A session with attendees. Zarrabian is also available for one-on-one meetings from September 1-4, 2020. Kintara focuses on developing cancer therapies, notably VAL-083 for glioblastoma multiforme and REM-001 for cutaneous metastatic breast cancer, both of which are in late-stage clinical trials aimed at addressing significant unmet medical needs.
Kintara Therapeutics, Inc. (KTRA) announced the closure of a private placement, selling 2,185 shares of Series C Convertible Preferred Stock at $1,000 per share, raising approximately $2.2 million. This follows an earlier $19.6 million from a previous closing. The proceeds will fund a registration study for VAL-083 and a 15-patient study for REM-001, alongside working capital. Both therapies target significant medical needs, with VAL-083 in GBM and REM-001 in CMBC. The Preferred Stock is convertible at $1.214 per share and accrues dividends.
Kintara Therapeutics (KTRA) announced a private placement offering of up to 2,435 shares of Series C Convertible Preferred Stock at $1,000 per share, aiming for gross proceeds of approximately $2.4 million. This follows a previous raising of $19.6 million. The funds will support clinical studies for VAL-083 in glioblastoma and REM-001 for metastatic breast cancer. The offering is expected to close by August 24, 2020, pending customary conditions. Notably, the Preferred Stock is convertible into common stock at $1.214 per share, with accrued dividends as previously disclosed.
Kintara Therapeutics (KTRA) announced it has regained compliance with NASDAQ's minimum bid price requirement, as confirmed in a letter received on August 19, 2020. The company's shares closed above $1.00 for ten consecutive business days, satisfying Listing Rule 5550(a)(2). Kintara is focused on developing innovative cancer therapies, including VAL-083 for GBM and REM-001 for CMBC. Both programs are in advanced clinical stages, with VAL-083 showing promise in various cancers and REM-001 achieving an 80% complete response in prior studies.